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The metastases of tumors often involve spread through the lymphatic system. This process, despite being integral to the morbidity and mortality of cancer, is not fully understood. In this study, Miyazaki et al. investigated the mechanism by which lymphatic endothelial cells are maintained. Specifically, they investigated the role of Prox1, a known embryonic homeobox-containing transcription factor, in lymphangiogenesis. Through *in vitro* and *in vivo* mice studies they were able to elucidate that Prox1 maintains the expression of tyrosine kinase platelet-derived growth factor receptor β, which is required for sustained lymphangiogenesis. Further, by inhibiting these signals through the PDGFRbβ / Fc chimeric protein, decreased formation of lymphatic vessels was observed. These exciting findings have begun to piece together the cascade of events that lead to metastases; this understanding will generate new possibilities in treatment. doi: [10.1111/cas.12476](10.1111/cas.12476)
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Cancer cells are known to be sensitive to a variety of chemotherapeutics, but may become resistant to one or more agents. Multidrug resistance poses a unique challenge in cancer therapy because drugs may lose their efficacy over time, while still maintaining their side-effect profile. A major focus of research into chemotherapeutics is to identify the mechanisms behind MDR. In this highly important work, Yan and colleagues used a cell culture model of lung cancer to investigate a mechanism of MDR known to involve the protein ataxia--telangiectasia mutant and the cytokine interleukin-6. In their experiment, the authors found that interleukin-6 had the ability to increase the resistance of lung cancer cells to multiple chemotherapeutics by activating the ataxia--telangiectasia mutant/nuclear factor-κB pathway. By uncovering the exact process by which these cells may acquire resistance to various interventions, the authors clear the way for new drug targets. doi: [10.1111/cas.12478](10.1111/cas.12478)
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There are many steps and processes in the progression of premalignant tumor cells to metastatic neoplasms. In colorectal cancer, the latency may be many years for this transformation to occur and the exact process through which this happens is the subject of significant research. In the exciting work presented here, Hamabe and coworkers investigate cancer-specific aerobic glycolysis and an important component in the process of tumor invasion into normal tissues. Using human surgical samples, the authors identified hexokinase 2 and phosphorylated pyruvate dehydrogenase-E1α, two gateway enzymes in glycolysis, as playing an important functional role in tumor invasiveness and the presence of lymph node metastases in patients. Perhaps most importantly, the authors found that, combined, these enzymes served as a prognostic factor for recurrence-free survival. This work carries vast implications in understanding tumor biology and in identifying important prognostic variables to better inform patients and guide treatment decisions. doi: [10.1111/cas.12487](10.1111/cas.12487)
